SHANGHAI, July 7, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and ...

Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s growth in IgAN and recent FSGS approval. More on TVTX stock.

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...

FDA grants accelerated approval to Vera's Trutakna for IgA nephropathy, first dual BAFF/APRIL inhibitor. Competes with ...

The U.S. Food and Drug Administration said on Tuesday it had approved Vera Therapeutics' drug to treat patients with a ...

By Siddhi Mahatole and Puyaan Singh July 7 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it had approved ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX) with bullish sentiments. Unlock powerful investing ...

Vera Therapeutics faces tough IgAN competition as Trutakna looks late and undifferentiated. A rich valuation adds risk. Read ...

Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgA nephropathy (IgAN) that will compete with ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

SNP and Palantir announced a strategic partnership at Transformation World 2026 to accelerate secure SAP transformations, alongside new Kyano agentic AI tools for data migration and unstructured data ...

Golden Heaven Group Holdings, a Nasdaq-listed amusement park rental operator in China, announced unaudited financial results for the six months ended 31 March 2026, its fiscal first half.